Advertisement

Topics

Astellas Pharma acquires Universal Cells for $102m

03:17 EST 15 Feb 2018 | Pharmaceutical Business Review

Astellas Pharma has acquired Universal Cells for $102.5m in a move to utilize the latter’s technology to produce pluripotent stem cells that have the potential to lower immunological rejection in various therapeutic areas.

Original Article: Astellas Pharma acquires Universal Cells for $102m

NEXT ARTICLE

More From BioPortfolio on "Astellas Pharma acquires Universal Cells for $102m"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...